Osobní účet
Osobní účet
Cyteir Therapeutics
Developer of the next generation of synthetic lethal therapies to treat cancer
Stránky společnosti2012
O společnosti
Total Funding
$156.7M
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.
Number of employees
11-50
Headquarters
Cambridge, Massachusetts, United States
Upisovatelé
Acuta Capital Partners, Ally Bridge Group, Ample Plus Fund, Avidity Partners, CaaS Capital Management, Janus Henderson Investors, RA Capital Management